Reata Pharmaceuticals, Inc. (RETA) Stock Competitors & Peer Comparison
See (RETA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RETA | $172.36 | +0.02% | 6.6B | -66.29 | -$2.60 | N/A |
| NVO | $42.95 | -5.77% | 195.8B | 10.34 | $4.26 | +4.05% |
| VRTX | $426.43 | -4.72% | 111.3B | 25.99 | $16.87 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $595.55 | -3.13% | 61.9B | 14.67 | $40.94 | +0.60% |
| ARGX | $801.86 | -4.08% | 51.7B | 37.08 | $22.55 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $287.10 | -4.93% | 39.5B | 74.09 | $3.99 | N/A |
| RVMD | $151.97 | -3.50% | 34.8B | -23.02 | -$7.11 | N/A |
| RPRX | $54.32 | -2.58% | 23.7B | 29.04 | $1.90 | +1.66% |
Stock Comparison
RETA vs NVO Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, NVO has a market cap of 195.8B. Regarding current trading prices, RETA is priced at $172.36, while NVO trades at $42.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas NVO's P/E ratio is 10.34. In terms of profitability, RETA's ROE is +0.47%, compared to NVO's ROE of +0.66%. Regarding short-term risk, RETA is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check NVO's competition here
RETA vs VRTX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, VRTX has a market cap of 111.3B. Regarding current trading prices, RETA is priced at $172.36, while VRTX trades at $426.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas VRTX's P/E ratio is 25.99. In terms of profitability, RETA's ROE is +0.47%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, RETA is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check VRTX's competition here
RETA vs VRNA Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RETA is priced at $172.36, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RETA's ROE is +0.47%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, RETA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check VRNA's competition here
RETA vs REGN Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, REGN has a market cap of 61.9B. Regarding current trading prices, RETA is priced at $172.36, while REGN trades at $595.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas REGN's P/E ratio is 14.67. In terms of profitability, RETA's ROE is +0.47%, compared to REGN's ROE of +0.14%. Regarding short-term risk, RETA is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check REGN's competition here
RETA vs ARGX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ARGX has a market cap of 51.7B. Regarding current trading prices, RETA is priced at $172.36, while ARGX trades at $801.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ARGX's P/E ratio is 37.08. In terms of profitability, RETA's ROE is +0.47%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, RETA is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ARGX's competition here
RETA vs SGEN Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RETA is priced at $172.36, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RETA's ROE is +0.47%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RETA is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check SGEN's competition here
RETA vs ALNY Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ALNY has a market cap of 39.5B. Regarding current trading prices, RETA is priced at $172.36, while ALNY trades at $287.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ALNY's P/E ratio is 74.09. In terms of profitability, RETA's ROE is +0.47%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, RETA is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ALNY's competition here
RETA vs RVMD Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, RVMD has a market cap of 34.8B. Regarding current trading prices, RETA is priced at $172.36, while RVMD trades at $151.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas RVMD's P/E ratio is -23.02. In terms of profitability, RETA's ROE is +0.47%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, RETA is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check RVMD's competition here
RETA vs RPRX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, RPRX has a market cap of 23.7B. Regarding current trading prices, RETA is priced at $172.36, while RPRX trades at $54.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas RPRX's P/E ratio is 29.04. In terms of profitability, RETA's ROE is +0.47%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, RETA is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check RPRX's competition here
RETA vs BNTX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, BNTX has a market cap of 23.2B. Regarding current trading prices, RETA is priced at $172.36, while BNTX trades at $88.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas BNTX's P/E ratio is -15.57. In terms of profitability, RETA's ROE is +0.47%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, RETA is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check BNTX's competition here
RETA vs UTHR Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, UTHR has a market cap of 23.1B. Regarding current trading prices, RETA is priced at $172.36, while UTHR trades at $536.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas UTHR's P/E ratio is 20.13. In terms of profitability, RETA's ROE is +0.47%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RETA is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check UTHR's competition here
RETA vs INSM Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, INSM has a market cap of 23B. Regarding current trading prices, RETA is priced at $172.36, while INSM trades at $102.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas INSM's P/E ratio is -18.41. In terms of profitability, RETA's ROE is +0.47%, compared to INSM's ROE of -1.30%. Regarding short-term risk, RETA is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check INSM's competition here
RETA vs ROIV Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ROIV has a market cap of 20.9B. Regarding current trading prices, RETA is priced at $172.36, while ROIV trades at $28.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ROIV's P/E ratio is -53.87. In terms of profitability, RETA's ROE is +0.47%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, RETA is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ROIV's competition here
RETA vs BGNE Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RETA is priced at $172.36, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RETA's ROE is +0.47%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, RETA is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check BGNE's competition here
RETA vs INCY Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, INCY has a market cap of 19.1B. Regarding current trading prices, RETA is priced at $172.36, while INCY trades at $93.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas INCY's P/E ratio is 13.50. In terms of profitability, RETA's ROE is +0.47%, compared to INCY's ROE of +0.29%. Regarding short-term risk, RETA is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check INCY's competition here
RETA vs DNA-WT Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RETA is priced at $172.36, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RETA's ROE is +0.47%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, RETA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check DNA-WT's competition here
RETA vs MRNA Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MRNA has a market cap of 18.3B. Regarding current trading prices, RETA is priced at $172.36, while MRNA trades at $45.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MRNA's P/E ratio is -5.66. In terms of profitability, RETA's ROE is +0.47%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, RETA is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check MRNA's competition here
RETA vs NBIX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, NBIX has a market cap of 16.2B. Regarding current trading prices, RETA is priced at $172.36, while NBIX trades at $154.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas NBIX's P/E ratio is 24.73. In terms of profitability, RETA's ROE is +0.47%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, RETA is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check NBIX's competition here
RETA vs GMAB Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, GMAB has a market cap of 15.6B. Regarding current trading prices, RETA is priced at $172.36, while GMAB trades at $24.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas GMAB's P/E ratio is 19.43. In terms of profitability, RETA's ROE is +0.47%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, RETA is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check GMAB's competition here
RETA vs JAZZ Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, JAZZ has a market cap of 14.6B. Regarding current trading prices, RETA is priced at $172.36, while JAZZ trades at $225.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas JAZZ's P/E ratio is 1938.67. In terms of profitability, RETA's ROE is +0.47%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, RETA is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check JAZZ's competition here
RETA vs ASND Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ASND has a market cap of 13.5B. Regarding current trading prices, RETA is priced at $172.36, while ASND trades at $217.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ASND's P/E ratio is 24.87. In terms of profitability, RETA's ROE is +0.47%, compared to ASND's ROE of -56.42%. Regarding short-term risk, RETA is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ASND's competition here
RETA vs BBIO Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, BBIO has a market cap of 12.8B. Regarding current trading prices, RETA is priced at $172.36, while BBIO trades at $63.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas BBIO's P/E ratio is -17.48. In terms of profitability, RETA's ROE is +0.47%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, RETA is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check BBIO's competition here
RETA vs EXEL Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, EXEL has a market cap of 12.6B. Regarding current trading prices, RETA is priced at $172.36, while EXEL trades at $48.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas EXEL's P/E ratio is 16.65. In terms of profitability, RETA's ROE is +0.47%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, RETA is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check EXEL's competition here
RETA vs KRTX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RETA is priced at $172.36, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RETA's ROE is +0.47%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RETA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check KRTX's competition here
RETA vs IONS Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, RETA is priced at $172.36, while IONS trades at $72.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas IONS's P/E ratio is -37.50. In terms of profitability, RETA's ROE is +0.47%, compared to IONS's ROE of -0.59%. Regarding short-term risk, RETA is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check IONS's competition here
RETA vs SMMT Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, SMMT has a market cap of 12.2B. Regarding current trading prices, RETA is priced at $172.36, while SMMT trades at $14.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas SMMT's P/E ratio is -9.88. In terms of profitability, RETA's ROE is +0.47%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, RETA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check SMMT's competition here
RETA vs AXSM Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, AXSM has a market cap of 11.8B. Regarding current trading prices, RETA is priced at $172.36, while AXSM trades at $220.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas AXSM's P/E ratio is -62.06. In terms of profitability, RETA's ROE is +0.47%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, RETA is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check AXSM's competition here
RETA vs RNAM Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, RETA is priced at $172.36, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas RNAM's P/E ratio is -17.39. In terms of profitability, RETA's ROE is +0.47%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, RETA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check RNAM's competition here
RETA vs MDGL Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MDGL has a market cap of 11.1B. Regarding current trading prices, RETA is priced at $172.36, while MDGL trades at $461.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MDGL's P/E ratio is -35.70. In terms of profitability, RETA's ROE is +0.47%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, RETA is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check MDGL's competition here
RETA vs BMRN Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, RETA is priced at $172.36, while BMRN trades at $54.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas BMRN's P/E ratio is 39.59. In terms of profitability, RETA's ROE is +0.47%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, RETA is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check BMRN's competition here
RETA vs ARWR Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ARWR has a market cap of 10.6B. Regarding current trading prices, RETA is priced at $172.36, while ARWR trades at $71.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ARWR's P/E ratio is -33.13. In terms of profitability, RETA's ROE is +0.47%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, RETA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ARWR's competition here
RETA vs RXDX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RETA is priced at $172.36, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RETA's ROE is +0.47%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RETA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check RXDX's competition here
RETA vs CYTK Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, RETA is priced at $172.36, while CYTK trades at $71.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CYTK's P/E ratio is -10.76. In terms of profitability, RETA's ROE is +0.47%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, RETA is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CYTK's competition here
RETA vs KRYS Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, KRYS has a market cap of 8.8B. Regarding current trading prices, RETA is priced at $172.36, while KRYS trades at $293.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas KRYS's P/E ratio is 39.96. In terms of profitability, RETA's ROE is +0.47%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RETA is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check KRYS's competition here
RETA vs IMGN Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RETA is priced at $172.36, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RETA's ROE is +0.47%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RETA is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check IMGN's competition here
RETA vs ABVX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ABVX has a market cap of 8.5B. Regarding current trading prices, RETA is priced at $172.36, while ABVX trades at $74.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ABVX's P/E ratio is -24.20. In terms of profitability, RETA's ROE is +0.47%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, RETA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ABVX's competition here
RETA vs BPMC Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RETA is priced at $172.36, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RETA's ROE is +0.47%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, RETA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check BPMC's competition here
RETA vs CERE Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RETA is priced at $172.36, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CERE's P/E ratio is -16.47. In terms of profitability, RETA's ROE is +0.47%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RETA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check CERE's competition here
RETA vs HALO Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, RETA is priced at $172.36, while HALO trades at $66.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas HALO's P/E ratio is 23.91. In terms of profitability, RETA's ROE is +0.47%, compared to HALO's ROE of +1.26%. Regarding short-term risk, RETA is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check HALO's competition here
RETA vs TECH Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, TECH has a market cap of 8B. Regarding current trading prices, RETA is priced at $172.36, while TECH trades at $49.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas TECH's P/E ratio is 72.56. In terms of profitability, RETA's ROE is +0.47%, compared to TECH's ROE of +0.05%. Regarding short-term risk, RETA is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check TECH's competition here
RETA vs IBRX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, RETA is priced at $172.36, while IBRX trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas IBRX's P/E ratio is -8.52. In terms of profitability, RETA's ROE is +0.47%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, RETA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check IBRX's competition here
RETA vs CORT Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, RETA is priced at $172.36, while CORT trades at $70.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CORT's P/E ratio is 201.26. In terms of profitability, RETA's ROE is +0.47%, compared to CORT's ROE of +0.08%. Regarding short-term risk, RETA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CORT's competition here
RETA vs MTSR Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RETA is priced at $172.36, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RETA's ROE is +0.47%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, RETA is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check MTSR's competition here
RETA vs PRAX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, RETA is priced at $172.36, while PRAX trades at $276.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas PRAX's P/E ratio is -25.01. In terms of profitability, RETA's ROE is +0.47%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, RETA is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check PRAX's competition here
RETA vs PCVX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, PCVX has a market cap of 7.1B. Regarding current trading prices, RETA is priced at $172.36, while PCVX trades at $47.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas PCVX's P/E ratio is -7.10. In terms of profitability, RETA's ROE is +0.47%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, RETA is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check PCVX's competition here
RETA vs ALKS Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ALKS has a market cap of 7B. Regarding current trading prices, RETA is priced at $172.36, while ALKS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ALKS's P/E ratio is 46.97. In terms of profitability, RETA's ROE is +0.47%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, RETA is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ALKS's competition here
RETA vs NUVL Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, NUVL has a market cap of 6.8B. Regarding current trading prices, RETA is priced at $172.36, while NUVL trades at $91.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas NUVL's P/E ratio is -15.35. In terms of profitability, RETA's ROE is +0.47%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, RETA is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check NUVL's competition here
RETA vs MRUS Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RETA is priced at $172.36, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RETA's ROE is +0.47%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, RETA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check MRUS's competition here
RETA vs IMVT Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, IMVT has a market cap of 6.7B. Regarding current trading prices, RETA is priced at $172.36, while IMVT trades at $30.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas IMVT's P/E ratio is -11.86. In terms of profitability, RETA's ROE is +0.47%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, RETA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check IMVT's competition here
RETA vs ACLX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RETA is priced at $172.36, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RETA's ROE is +0.47%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RETA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check ACLX's competition here
RETA vs KYMR Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, KYMR has a market cap of 6.5B. Regarding current trading prices, RETA is priced at $172.36, while KYMR trades at $74.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas KYMR's P/E ratio is -21.92. In terms of profitability, RETA's ROE is +0.47%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, RETA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check KYMR's competition here
RETA vs CNTA Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, RETA is priced at $172.36, while CNTA trades at $39.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CNTA's P/E ratio is -22.39. In terms of profitability, RETA's ROE is +0.47%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, RETA is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CNTA's competition here
RETA vs PTCT Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, RETA is priced at $172.36, while PTCT trades at $68.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas PTCT's P/E ratio is -29.06. In terms of profitability, RETA's ROE is +0.47%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, RETA is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check PTCT's competition here
RETA vs PTGX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, PTGX has a market cap of 6.1B. Regarding current trading prices, RETA is priced at $172.36, while PTGX trades at $94.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas PTGX's P/E ratio is -52.35. In terms of profitability, RETA's ROE is +0.47%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, RETA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check PTGX's competition here
RETA vs RYTM Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, RETA is priced at $172.36, while RYTM trades at $83.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas RYTM's P/E ratio is -28.07. In terms of profitability, RETA's ROE is +0.47%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, RETA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check RYTM's competition here
RETA vs CELC Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CELC has a market cap of 6B. Regarding current trading prices, RETA is priced at $172.36, while CELC trades at $91.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CELC's P/E ratio is -31.53. In terms of profitability, RETA's ROE is +0.47%, compared to CELC's ROE of -2.45%. Regarding short-term risk, RETA is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CELC's competition here
RETA vs COGT Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, RETA is priced at $172.36, while COGT trades at $33.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas COGT's P/E ratio is -16.04. In terms of profitability, RETA's ROE is +0.47%, compared to COGT's ROE of -0.83%. Regarding short-term risk, RETA is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check COGT's competition here
RETA vs BLTE Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, RETA is priced at $172.36, while BLTE trades at $135.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas BLTE's P/E ratio is -57.65. In terms of profitability, RETA's ROE is +0.47%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, RETA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check BLTE's competition here
RETA vs TGTX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, TGTX has a market cap of 5.7B. Regarding current trading prices, RETA is priced at $172.36, while TGTX trades at $36.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas TGTX's P/E ratio is 13.08. In terms of profitability, RETA's ROE is +0.47%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, RETA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check TGTX's competition here
RETA vs SRRK Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, RETA is priced at $172.36, while SRRK trades at $45.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas SRRK's P/E ratio is -13.74. In terms of profitability, RETA's ROE is +0.47%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, RETA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check SRRK's competition here
RETA vs CDTX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RETA is priced at $172.36, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RETA's ROE is +0.47%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, RETA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check CDTX's competition here
RETA vs ABCM Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RETA is priced at $172.36, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RETA's ROE is +0.47%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RETA and ABCM have similar daily volatility (0.08).Check ABCM's competition here
RETA vs ISEE Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RETA is priced at $172.36, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RETA's ROE is +0.47%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RETA is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ISEE's competition here
RETA vs APLS Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, RETA is priced at $172.36, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas APLS's P/E ratio is 38.35. In terms of profitability, RETA's ROE is +0.47%, compared to APLS's ROE of +0.40%. Regarding short-term risk, RETA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check APLS's competition here
RETA vs CRSP Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, RETA is priced at $172.36, while CRSP trades at $52.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CRSP's P/E ratio is -8.78. In terms of profitability, RETA's ROE is +0.47%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, RETA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CRSP's competition here
RETA vs CGON Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CGON has a market cap of 5.2B. Regarding current trading prices, RETA is priced at $172.36, while CGON trades at $56.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CGON's P/E ratio is -25.31. In terms of profitability, RETA's ROE is +0.47%, compared to CGON's ROE of -0.23%. Regarding short-term risk, RETA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CGON's competition here
RETA vs LQDA Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, LQDA has a market cap of 5.2B. Regarding current trading prices, RETA is priced at $172.36, while LQDA trades at $55.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas LQDA's P/E ratio is 345.56. In terms of profitability, RETA's ROE is +0.47%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, RETA is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check LQDA's competition here
RETA vs FBIOX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, RETA is priced at $172.36, while FBIOX trades at $25.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas FBIOX's P/E ratio is N/A. In terms of profitability, RETA's ROE is +0.47%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, RETA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check FBIOX's competition here
RETA vs APGE Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, APGE has a market cap of 4.9B. Regarding current trading prices, RETA is priced at $172.36, while APGE trades at $79.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas APGE's P/E ratio is -18.31. In terms of profitability, RETA's ROE is +0.47%, compared to APGE's ROE of -0.33%. Regarding short-term risk, RETA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check APGE's competition here
RETA vs MIRM Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, RETA is priced at $172.36, while MIRM trades at $92.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MIRM's P/E ratio is -7.08. In terms of profitability, RETA's ROE is +0.47%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, RETA is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check MIRM's competition here
RETA vs TERN Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RETA is priced at $172.36, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas TERN's P/E ratio is -51.41. In terms of profitability, RETA's ROE is +0.47%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RETA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check TERN's competition here
RETA vs LEGN Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, LEGN has a market cap of 4.7B. Regarding current trading prices, RETA is priced at $172.36, while LEGN trades at $35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas LEGN's P/E ratio is -18.49. In terms of profitability, RETA's ROE is +0.47%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, RETA is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check LEGN's competition here
RETA vs CAI Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, RETA is priced at $172.36, while CAI trades at $16.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CAI's P/E ratio is -5.96. In terms of profitability, RETA's ROE is +0.47%, compared to CAI's ROE of +0.06%. Regarding short-term risk, RETA is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CAI's competition here
RETA vs LGND Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, RETA is priced at $172.36, while LGND trades at $232.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas LGND's P/E ratio is 29.92. In terms of profitability, RETA's ROE is +0.47%, compared to LGND's ROE of +0.16%. Regarding short-term risk, RETA is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check LGND's competition here
RETA vs FOLD Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RETA is priced at $172.36, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RETA's ROE is +0.47%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RETA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check FOLD's competition here
RETA vs AKRO Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RETA is priced at $172.36, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RETA's ROE is +0.47%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, RETA is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check AKRO's competition here
RETA vs ALPN Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RETA is priced at $172.36, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RETA's ROE is +0.47%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RETA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check ALPN's competition here
RETA vs EWTX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, RETA is priced at $172.36, while EWTX trades at $37.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas EWTX's P/E ratio is -24.25. In terms of profitability, RETA's ROE is +0.47%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, RETA is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check EWTX's competition here
RETA vs ERAS Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ERAS has a market cap of 4.3B. Regarding current trading prices, RETA is priced at $172.36, while ERAS trades at $13.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ERAS's P/E ratio is -14.86. In terms of profitability, RETA's ROE is +0.47%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, RETA is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ERAS's competition here
RETA vs SYRE Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, SYRE has a market cap of 4.3B. Regarding current trading prices, RETA is priced at $172.36, while SYRE trades at $68.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas SYRE's P/E ratio is -33.27. In terms of profitability, RETA's ROE is +0.47%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, RETA is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check SYRE's competition here
RETA vs MANE Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, RETA is priced at $172.36, while MANE trades at $100.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MANE's P/E ratio is -38.50. In terms of profitability, RETA's ROE is +0.47%, compared to MANE's ROE of -0.95%. Regarding short-term risk, RETA is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check MANE's competition here
RETA vs OPT Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RETA is priced at $172.36, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas OPT's P/E ratio is -1.52. In terms of profitability, RETA's ROE is +0.47%, compared to OPT's ROE of +0.88%. Regarding short-term risk, RETA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check OPT's competition here
RETA vs XENE Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, RETA is priced at $172.36, while XENE trades at $52.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas XENE's P/E ratio is -11.36. In terms of profitability, RETA's ROE is +0.47%, compared to XENE's ROE of -0.49%. Regarding short-term risk, RETA is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check XENE's competition here
RETA vs TVTX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, TVTX has a market cap of 4.2B. Regarding current trading prices, RETA is priced at $172.36, while TVTX trades at $42.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas TVTX's P/E ratio is -90.08. In terms of profitability, RETA's ROE is +0.47%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, RETA is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check TVTX's competition here
RETA vs MRTX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RETA is priced at $172.36, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RETA's ROE is +0.47%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RETA is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check MRTX's competition here
RETA vs VCYT Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, RETA is priced at $172.36, while VCYT trades at $46.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas VCYT's P/E ratio is 44.61. In terms of profitability, RETA's ROE is +0.47%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, RETA is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check VCYT's competition here
RETA vs CPRX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, RETA is priced at $172.36, while CPRX trades at $31.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CPRX's P/E ratio is 18.08. In terms of profitability, RETA's ROE is +0.47%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, RETA is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CPRX's competition here
RETA vs RYZB Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RETA is priced at $172.36, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RETA's ROE is +0.47%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RETA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check RYZB's competition here
RETA vs DNTH Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, DNTH has a market cap of 3.7B. Regarding current trading prices, RETA is priced at $172.36, while DNTH trades at $83.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas DNTH's P/E ratio is -21.15. In terms of profitability, RETA's ROE is +0.47%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, RETA is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check DNTH's competition here
RETA vs CBAY Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RETA is priced at $172.36, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RETA's ROE is +0.47%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RETA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check CBAY's competition here
RETA vs NAMS Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, RETA is priced at $172.36, while NAMS trades at $31.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas NAMS's P/E ratio is -17.86. In terms of profitability, RETA's ROE is +0.47%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, RETA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check NAMS's competition here
RETA vs ACAD Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, RETA is priced at $172.36, while ACAD trades at $20.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ACAD's P/E ratio is 9.74. In terms of profitability, RETA's ROE is +0.47%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, RETA is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ACAD's competition here
RETA vs KNSA Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, RETA is priced at $172.36, while KNSA trades at $46.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas KNSA's P/E ratio is 53.22. In terms of profitability, RETA's ROE is +0.47%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, RETA is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check KNSA's competition here
RETA vs CRNX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CRNX has a market cap of 3.6B. Regarding current trading prices, RETA is priced at $172.36, while CRNX trades at $32.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CRNX's P/E ratio is -6.72. In terms of profitability, RETA's ROE is +0.47%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, RETA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CRNX's competition here
RETA vs VKTX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, RETA is priced at $172.36, while VKTX trades at $29.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas VKTX's P/E ratio is -7.53. In terms of profitability, RETA's ROE is +0.47%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, RETA is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check VKTX's competition here
RETA vs SWTX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RETA is priced at $172.36, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RETA's ROE is +0.47%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, RETA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check SWTX's competition here
RETA vs DNLI Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, RETA is priced at $172.36, while DNLI trades at $19.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas DNLI's P/E ratio is -7.09. In terms of profitability, RETA's ROE is +0.47%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, RETA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check DNLI's competition here
RETA vs BEAM Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, BEAM has a market cap of 3.2B. Regarding current trading prices, RETA is priced at $172.36, while BEAM trades at $28.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas BEAM's P/E ratio is -63.55. In terms of profitability, RETA's ROE is +0.47%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, RETA is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check BEAM's competition here
RETA vs TLX Comparison June 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, RETA is priced at $172.36, while TLX trades at $9.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas TLX's P/E ratio is -471.00. In terms of profitability, RETA's ROE is +0.47%, compared to TLX's ROE of -0.02%. Regarding short-term risk, RETA is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check TLX's competition here